Maastricht, 23 December 2021 – RegMed XB has received the first subsidy of 23 million euros from the Ministry of Economic Affairs and Climate Policy. This is the start of the realization of the national pilot factory for regenerative medicine after the Dutch cabinet decided on 9 April this year to fund the National Growth Fund proposal of RegMed XB. This amounts to a total of EUR 56 million. Through the cooperation within RegMed XB, the funds will be used for the high-quality construction, furnishing and staffing of this pilot factory in the various regions. The realization of the pilot plant not only contributes to healthcare alone, it is also a means to increase the innovation power of the Netherlands.
A unique regional cooperation
The new facilities in the regions together form the pilot plant. They cover the entire chain of development and production of stem cells, mini-organs, tissues and smart (bio)materials.
Greater innovation power
The Netherlands is already one of the frontrunners in the field of regenerative medicine. The pilot plant provides an important boost in this emerging industry. Thanks to the support of the National Growth Fund and the investment of provinces, private parties and knowledge institutions, the ecosystem is created in which parties work closely together and that brings a cure for chronic diseases a step closer.
Regenerative Medicine Crossing Borders (RegMed XB) is a patient-driven public-private partnership dedicated to bringing affordable regenerative medicine solutions to patients with chronic diseases. Regenerative medicine focuses on repairing damage to cells, tissues and organs so that chronic diseases can be prevented or cured. For this purpose, stem cells, mini-organs, tissues and smart (bio)materials are used. RegMed XB connects top clusters in the field of regenerative medicine in different regions in the Netherlands (Leiden, Brabant, Utrecht and Limburg), and Flanders (Leuven). RegMed XB's ambitious research currently focuses on curing type 1 diabetes, kidney failure, osteoarthritis and cardiovascular disease.